Agios Pharmaceuticals Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 2025 Revenue: $20 million from PYRUKYND, an 86% increase year-over-year and a 55% sequential increase from Q3 2025.

Full Year 2025 Revenue: Totaled $54 million, reflecting strong growth in the PK deficiency market.

Cash Position: Approximately $1.2 billion in cash, cash equivalents, and marketable securities, providing operational flexibility.

R&D Expenses: $88.1 million in Q4, up from the previous year, driven by early-stage pipeline advancements.

SG&A Expenses: $51.6 million in Q4, roughly flat year-over-year.

2Strategic Updates and Business Highlights

AQVESME Launch: Received FDA approval for AQVESME for thalassemia in December 2025; launch is underway with 44 prescriptions written by January 30, 2026.

Pipeline Expansion: Focus on expanding the PK activation franchise into sickle cell disease and lower-risk myelodysplastic syndrome (MDS).

Upcoming Catalysts: Anticipated top-line results from Tebapivat in sickle cell disease and MDS in 2026, along with a pre-sNDA meeting with the FDA for mitapivat.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected U.S. PK deficiency revenues between $45 million and $50 million.

Operating Expenses: Anticipated to remain flat compared to 2025, with investments focused on maximizing AQVESME's launch and exploring sickle cell disease opportunities.

Path to Profitability: Agios aims for profitability through existing commercial presence in thalassemia and PK deficiency, with a clear path outlined.

4Challenges and Points of Concern

Revenue Recognition Timeline: The conversion from prescriptions to treatment initiation is expected to take 10-12 weeks, which may delay revenue recognition.

Ex-U.S. Revenue Decline: Anticipated sequential decline in international revenues as patients transition from a managed access program to commercial supply.

Regulatory Risks: Uncertainty surrounding the outcomes of the pre-sNDA meeting with the FDA for mitapivat, including the potential for accelerated approval versus full approval.

5Notable Q&A Insights

AQVESME Launch Dynamics: Initial prescriptions are primarily from transfusion-dependent patients, with expectations for growth in non-transfusion-dependent patients as the launch progresses.

Payer Dynamics: Initial market access has been smooth, with no significant hurdles reported; however, the majority of patients are expected to go through medical exceptions for insurance authorization.

Tebapivat Expectations: The Phase II trial for sickle cell disease is designed to explore dose optimization, with the potential for higher hemoglobin responses based on previous data.

Commercial Readiness for Sickle Cell: The team is preparing for a potential launch in sickle cell disease, leveraging the infrastructure built for PK deficiency and thalassemia. Overall, Agios Pharmaceuticals is entering 2026 with strong momentum from the AQVESME launch and a robust pipeline, while navigating challenges related to revenue recognition and regulatory approvals.